Russia'n firm Grumant invests $45 million in herbal APIs plant
Grumant, one of Russia’s largest manufacturers of pharmaceutical ingredients based on medicinal herbs, plans to invest 1.6 billion roubles ($45 million) in a new production plant which is expected to be built in Russia in 2014.
The new plant is likely to be located in Novgorod (Central Russia) and will focus on the supplies of raw materials for the needs of Russia’s leading producers of drugs and dietary supplements, as well as Russian plants, owned by foreign companies. The payback period for the project is between five and six years.
The new plant will specialize in the production of pharmaceutical substances, extracts, as well as essential oils for the needs of pharmaceutical and cosmetic industries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze